CytoSorbents expects operating cash flow breakeven in second half of 2026
CTSO•CytoSorbents expects operating cash flow breakeven in the second half of 2026 and is targeting profitability in late 2027–2028. Second-quarter revenue was $9.6 million, operating cash burn was $200,000 excluding restructuring payments, and quarter-end cash, cash equivalents and restricted cash totaled $5.9 million.
1. Cash flow outlook
CytoSorbents expects operating cash flow breakeven in the second half of 2026 and is targeting profitability in late 2027–2028. Second-quarter 2026 operating cash burn was $200,000, excluding $200,000 in restructuring payments; quarter-end cash, cash equivalents and restricted cash totaled $5.9 million. Revenue reached $9.6 million, and the company has cut headcount by 23% since September 2025.
